A new technology for management of diabetes is cost-effective for patients in the US with type 1 diabetes compared with traditional treatments.

Mizuho initiated coverage of Embecta (EMBC) with a Neutral rating and $15 price target The firm says its rating balances the company’s ...

Actor Yoon Hyun-sook told about his recent situation while battling type 1 diabetes.On the 9th, we did a time-slip in our 20s ...

This market research report provides an in-depth analysis of the Injectable Drug Delivery Market, projecting significant ...

Jesse Lee Fauls, 42, of DuBois, who was found with an illegal firearm and drugs was sentenced to state prison by President Judge Fredric J. Ammerman Monday at ...